Hims & Hers Launches New Peptide Therapy, Acknowledging Efficacy Still Needs Further Research
Key Points
Hims & Hers Health announced the launch of five new peptide and longevity-related formulations produced in-house in the U.S. as part of its Peptides+ platform's initial product rollout. The telehealth company’s new formulations include: growth hormone-releasing peptide (Sermorelin), glutathione, NAD+, vitamin B12, and L-carnitine; none of these products have received FDA approval. The backdrop for this launch is the federal government easing regulatory restrictions on certain unapproved peptide formulations.
Hims & Hers stated on Wednesday that the Peptides+ platform has launched five locally compounded peptide and longevity therapy formulations in the U.S., all of which have not yet received regulatory approval. Even while releasing new products, Hims & Hers acknowledged that there is still a lot of information to explore regarding the optimal use and actual efficacy of peptides, highlighting the inherent uncertainties in this rapidly growing sector.
Peptides are short chains of amino acids. Previously, the federal government relaxed restrictions on certain unapproved peptide formulations, which have become popular among fitness and anti-aging enthusiasts, who claim they help with muscle gain, accelerate injury recovery, and combat aging, but the vast majority lack high-quality clinical trial evidence in humans.
A company spokesperson revealed that Hims began taking reservations for this batch of peptide products at the end of October, with over 10,000 people signing up within 15 days.
These custom compounded formulations have not received FDA approval. However, Hims claims that these products are compliant with the law, compounded by licensed pharmacies that adhere to strict quality standards, hold state pharmacy board licenses, and undergo regular inspections.
Product List:
- Sermorelin: A peptide that stimulates growth hormone release, marketed for injury recovery, optimizing body composition, and anti-aging;
- Glutathione: Focused on anti-aging and post-exercise recovery;
- NAD+ (Nicotinamide Adenine Dinucleotide): A coenzyme involved in cellular metabolism;
- Vitamin B12: Used for red blood cell synthesis, DNA, and maintaining normal nerve function;
- L-Carnitine: An amino acid derivative that helps the body convert fat into energy.
The FDA has indeed approved some prescription forms of B12 and L-carnitine, but the approved indications primarily address diagnosed nutrient deficiencies.
Hims plans to continue adding U.S.-produced peptide therapies, including BPC-157 (derived from human gastric juice protein, unapproved, marketed for tissue repair) and TB-500 (derived from natural human protein, unapproved, promoted for systemic soft tissue repair and improving flexibility). Most existing studies on these substances are animal experiments, lacking human data.
Usage Process
Platform users wishing to use these products must first be evaluated by a licensed physician trained in peptide therapy regarding their health history and goals; if the assessment is passed, the physician can customize a personalized plan as needed. The company will follow up with users online to confirm whether the expected effects are achieved.
Dr. Anant Vinjamoori, Chief Medical Officer of Hims, stated in an interview: "If the effects do not meet expectations, we need to make adjustments. Adjust the dosage if appropriate, or switch to a more suitable formulation; of course, in some cases, we will refer to other medical channels."
He admitted that the optimal use of peptides still has many unknowns: "We do not have the comprehensive data that we have for conventional drugs. We have the opportunity to standardize this, and with our scale, expertise, and resources, it is our responsibility, and we are willing to take the lead in exploring."
Vinjamoor added that individuals with significant underlying conditions such as cardiovascular disease, liver disease, or kidney disease are currently not suitable for using these compounded formulations.
Renowned neuroscientist, podcast host, and Stanford Medical School professor Andrew Huberman has now joined the Hims board. In a statement, he said these formulations are legitimate medical means, not just wellness trends; Hims provides users with a safe channel for use through reliable raw materials and physician supervision.
Potential Risks and Controversies of Peptide Products
However, medical experts have raised concerns about the mass marketing of such peptide products in the U.S. and the direct sale model by telehealth platforms.
Tufts University chemistry professor Joshua Kritzer stated: "Peptides should be viewed like all drugs that have not undergone rigorous testing. Without solid clinical trials, only scattered anecdotal feedback is insufficient to justify injecting these substances into the body."
He pointed out that the lack of large-scale clinical trials prevents researchers from ruling out the possibility of serious, rare adverse reactions associated with peptides; it is precisely these risks that lead regulatory agencies to reject or even recall drugs that initially seem effective after complete human trials.
Paul Knoepfler, a professor of cell biology and human anatomy at the University of California, Davis Health Center, noted that without trial data, telehealth companies, physicians, and pharmacies do not have sufficient basis to determine appropriate dosages. Although many users rely on online anecdotal experiences, the standard dosage for these products has not been established.
One risk is that injecting excessive synthetic peptides may cause the body to recognize them as foreign substances, triggering abnormal and severe immune reactions. "The regulations around peptides are very vague; you simply do not know how much dosage is needed to achieve the expected effect, and how much dosage will bring high risks." However, he also believes that maintaining sufficient communication between users and doctors would be better; telehealth physicians need to fully inform about product risks and unknowns, and assess past medical history, tumor history, and concurrent medication situations.
Hims' accompanying plan aligns with this thinking: users purchasing peptide longevity products can opt for the Care+ value-added service, which includes ongoing medical support, such as biannual laboratory tests to track indicators and 24-hour consultation with trained peptide physicians.
However, Kritzer still believes that physicians conducting online consultations and relying on mail-order platforms for management do not have sufficient oversight to support prescription medication, especially for these unapproved formulations.
Regulatory Background
Hims can legally sell some of these peptide formulations due to a significant shift in regulatory policy by the U.S. Department of Health and Human Services (HHS). The department issued new regulations in October: during the formal rule review period, the FDA will not take enforcement action against licensed pharmacies, federal medical institutions, or physicians, allowing them to compound and distribute six unapproved peptides. This does not mean the FDA has formally approved these peptides; it simply means they are temporarily not enforcing; even if these peptides are not on the official list of raw materials allowed for compounding by the FDA, pharmacies can still supply them.
During the Biden administration in 2023, the FDA had restricted the production of popular peptide formulations by compounding pharmacies due to safety, impurity, and immune reaction risks. HHS Secretary Robert F. Kennedy Jr. supports expanding the accessibility of peptides, claiming to be a staunch supporter of such therapies, believing that the ban would force Americans to purchase overseas products of questionable safety. He himself has publicly used BPC-157 to treat muscle injuries.
Additionally, Hims acquired a peptide production facility in California back in February 2025, equipped with advanced peptide synthesis equipment.
Evidence Status (Limitations of Existing Research)
The effectiveness evidence for different peptides varies:
- A review summarizing 113 studies (small human trials + animal experiments): No qualified clinical endpoint trials have proven that intravenous/intramuscular injection of NAD+ can combat aging, improve energy, or health indicators.
- L-Carnitine: An analysis including 37 trials showed that subjects lost an average of about 2.7 pounds, but this conclusion cannot be directly applied to compounded injectable forms.
- B12 formulations: The mainstream use is to treat diagnosed deficiencies, not for preventive health; a U.S. survey showed that only 3.6% of adults have B12 deficiency.
- Glutathione: Evidence is weak, with many market claims about intravenous injection for skin whitening, but the FDA has not approved this indication. A study published in the journal of the Pakistan Association of Dermatologists showed that intravenous glutathione has limited whitening effects, and the effects diminish over time. The FDA issued a warning in August: it received at least 30 reports of adverse reactions, with patients experiencing discomfort after using intravenous glutathione from different compounding pharmacies, either alone or in combination. The glutathione involved all came from the same wholesaler, with the raw materials labeled as dietary supplement grade, not suitable for making injectable medications; two Texas pharmacies recalled products due to excessive endotoxin levels.
The above studies and adverse reaction reports cannot be directly equated with the performance of Hims' compounded formulations, but clearly indicate that the data on related therapies is currently very limited, and many questions remain unanswered.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Should You Buy Amazon Stock Before the Holiday Season?

Nvidia's Board of Directors Is Not Planning to Reinstate Jensen Huang. But There's Still Another Way He Could Return as CEO

4 Financial Stocks to Buy That Gained in 2022's Bear Market While the S&P 500 Lost 19%

Relaxed but Ruined: The Law That Sells Your Seized Bitcoins Before Your Trial Arrives at the Senate on Thursday

Bitcoin options flash warning as downside premiums surge ahead of Fed minutes

Anthropic’s Claude completes a 16-hour human research job in under 3 hours

Is Micron Next to Announce a Stock Split?

Elon Musk Deepfake Confronts 500,000 People: Coinbase's AI Agent Blocks 99% of Scam Attempts

IonQ Stock Plunged 48% in Six Months. Is It a Bargain Buy?

Hackers from Binance Target Ethereum! Moving Hundreds of Thousands of ETH

Bill Gurley: Free AI is Google's 'top' strategy against Anthropic

Tencent: WorkBuddy Achieves Annualized Revenue of Over $500 Million in Seven Days, More Than Twice That of Tencent Meeting

History Says AGNC's Dividend Can Survive a Stock Market Crash -- but Not Always at Full Size

With Democrats to Control Congress, Is It Better to Buy Bitcoin or an Index Fund?

Solana Foundation Acquires Majority Stake in CoinGecko, A Crypto Traffic Battle Unfolds Behind 18 Million Users

I've Been Wrong About Paypal Stock for 2 Years. Here's Why I'm Finally Changing My Mind.

AI Will Make the Next 12 Months 'a Slaughterhouse' for Crypto Security: Anchorage Exec

Bitcoin miners found a way to profit without mining BTC, but the advantage may not last

IBC Protocol: Proof Matters, Not the Messenger

Wells Fargo Raises Disney Target Price to $140, Positive Outlook for Theme Park Business

Prediction: $200 a Month Invested in SpaceX Could Be Worth This Much by 2035

Is the Stock Market Really in an AI Bubble? Wall Street's Doomsayers Are Ignoring Crucial Facts.

AI Agent Faces Obstacles: Controllable Permissions More Urgent than Payments

Warnings Behind 50 Authorizations: How TBC Tightens Signature Permissions

Texas Approves SpaceX Supercomputer Power Plant Permit After Abbott Lifts Approval Freeze

a16z Frontier Explores AI Agent Sector, Uncovering a New Startup Opportunity

Tesla Is Now Taking Cybercab Orders. Here's Where I Think the Stock Will Be in 2030.

Brothers Exploit Ethereum Vulnerability, Acquiring $25 Million and Found Not Guilty

Tencent Q3 Earnings Preview: Profit May End 16-Quarter Growth, AI Spending and Cash Flow Become Revaluation Focus







